Nilutamide Tablet shortage
Nilutamide Tablet is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Oct 5, 2026.
Advanz Pharma is stopping production of nilutamide 150 mg tablets, and this change is permanent. The same strength is still listed as available from ANI Pharmaceuticals.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Nilutamide Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Dec 1, 2025Currently in shortage2 of 2 products affected.
-
Dec 1, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Advanz Pharma (US) Corp. 📞 847-283-7921 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Nilandron, Tablet, 150 mg (NDC 66993-212-38) | — | — | Product to expire in March 2026; Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Nilandron, Tablet, 150 mg (NDC 59212-111-14) | — | — | Product to expire in March 2026; Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Nilutamide Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Nilutamide Tablet? options further down this page.
Why is Nilutamide Tablet in shortage?
Advanz Pharma (US) Corp. has reported to the FDA that it is permanently stopping the manufacture of Nilandron (nilutamide) 150 mg tablets. Both package sizes on file with the FDA — NDC 59212-111-14 and NDC 66993-212-38 — are affected. The company notes that existing supply of these tablets is expected to expire in March 2026, after which no further product from this manufacturer will be available.
It's worth knowing that the FDA did not share a specific public reason for why Advanz Pharma made this decision to stop making the drug — just that the discontinuation is happening. This report reflects only what Advanz Pharma has filed with the FDA, so it speaks only to their product and not to any other manufacturers.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Nilutamide Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Nilutamide Tablet?
Nilutamide (brand name Nilandron) 150 mg tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The 150 mg strength — the only strength of this medicine — has no available source from the manufacturer that filed this report. The reason given is that the maker, Advanz Pharma, is discontinuing production, and the existing product is set to expire in March 2026. Because this is a planned discontinuation rather than a temporary delay, the supply problem from this manufacturer may be permanent. For that reason, a conversation with your prescriber is the right next step.
Please keep this in mind:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers, since local stock does not always match national reports.
- The same medicine, nilutamide 150 mg tablets, is listed from another maker (ANI Pharmaceuticals). Your pharmacy may be able to source it, though it may not be in local stock.
- Because this manufacturer is discontinuing the product, talk with your prescriber or pharmacist about a clinician-chosen plan going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Nilutamide Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Nilutamide Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Nilutamide | NILUTAMIDE 150 mg/1 | Tablet · Oral | ANI Pharmaceuticals, Inc. | 62559-0173-31 |
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Nilutamide 150 mg | ANI | 30 tablets | — | — | FDA listed |
| Nilutamide 150 mg | Prasco | 30 tablets | — | — | Discontinued |
| Nilandron 150 mg | Concordia | 30 tablets | — | — | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Nilutamide Tablet — that fall in the same broad treatment class (antineoplastic - antiandrogenic agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Nilutamide Tablet shortage FAQs
Is Nilutamide Tablet in shortage?
Which products are affected?
When will Nilutamide Tablet be available again?
Can I still get Nilutamide somewhere?
What should I do if I take Nilutamide Tablet?
Still have a question about the Nilutamide Tablet shortage?
Ask a pharmacist about this shortage →View Nilutamide Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.